Klisyri

Tirbanibulin, the active ingredient in Klisyri, is a Src kinase inhibitor presented as a 1% w/w topical solution for topical use. It is indicated for the treatment of actinic keratosis on the face and scalp in adult patients, providing a localized therapeutic option.

GNH USA supplies Klisyri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled distribution and regulatory compliance across global markets, and providing reliable logistics for timely delivery to meet local health authority requirements.

Klisyri (tirbanibulin) is a topical Src kinase inhibitor employed in dermatologic practice for the management of premalignant skin lesions caused by chronic sun exposure.

- Actinic keratosis of the face: reduces precancerous lesions on facial skin. - Actinic keratosis of the scalp: clears lesions on the scalp area. - Field‑directed therapy for actinic keratosis: treats multiple lesions within a treated area, improving overall lesion burden.

Klisyri may cause local skin reactions, most of which are mild to moderate and resolve after treatment.

Common Side Effects: - Erythema: redness at the application site. - Crusting: formation of a dry scab over treated lesions. - Pruritus: itching of the treated area. - Pain or tenderness: discomfort during or after application. - Swelling: mild edema around the lesion. - Dryness or flaking of skin.

Serious or Rare Side Effects: - Severe allergic reaction: hives, swelling, or difficulty breathing. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Bullous dermatitis: blister formation. - Secondary skin infection at the site. - Persistent ulceration or necrosis. - Uncontrolled pain requiring medical attention.

Before using Klisyri, consider the following safety measures.

- Pregnancy: safety not established; avoid use unless clearly needed. - Breastfeeding: unknown risk; weigh benefits against potential exposure. - Application site: apply only to intact skin; avoid eyes, mucous membranes, and open wounds. - Surface area: do not exceed the prescribed treatment area or duration. - Monitoring: discontinue and seek medical advice if severe local reactions develop. - Store at room temperature: keep in the original container, protect from light and moisture.

Klisyri has limited systemic absorption, but certain topical or systemic agents may influence its safety or efficacy.

Major Interactions (Avoid): - Concurrent use of other topical chemotherapeutic agents on the same area: may increase irritation. - Systemic immunosuppressants: could impair wound healing.

Moderate Interactions (Monitor Closely): - Topical corticosteroids applied to the same site: may reduce tirbanibulin efficacy. - Phototherapy or intense UV exposure: may heighten skin sensitivity. - Co‑application with other keratolytic agents: may enhance local irritation.